Spectrum Vascular Announces New Top-Tier Leadership

Spectrum Vascular is welcoming two new faces to its top management team. The company recently appointed Ken Miller as CEO and Doug Shook as chief commercial officer (CCO).

“Ken and Doug are proven leaders who share our values and vision,” SK Capital Managing Director Jon Borell said. “The Spectrum Vascular Board of Directors, as well as the SK Capital and Event Capital Strategies teams, are thrilled to partner with them as we position Spectrum for its next chapter.”

A seasoned executive with more than 35 years of leadership experience in the medical device industry, Miller brings a proven ability to drive commercial and operational excellence across both growth-stage and established healthcare organizations. He joins Spectrum from KORU Medical Systems, where he served as CCO since 2023. Prior to KORU, Miller held executive leadership positions at Nasco Healthcare, Becton Dickinson & Company, and Novo Nordisk, where he led high-performing teams, expanded market presence and delivered consistent revenue growth.

“I am honored to join Spectrum Vascular at such a critical stage in its journey,” Miller stated. “The company’s commitment to patient care and innovation, combined with the recent support from SK Capital, create a strong foundation for growth. I look forward to working with the Spectrum team to elevate our impact and expand access to Spectrum’s critical care technologies.”

Shook brings to his new role more than two decades of commercial leadership experience in the medical technology space, as well as expertise in driving go-to-market strategies and scaling customer engagement. He joins Spectrum from ICU Medical, where he served as the Global Business Unit leader for Vascular Access and led commercial operations across the vascular access portfolios. Prior to ICU Medical, Shook held commercial leadership roles at Smiths Medical and Access Scientific, manufacturers of premium vascular access devices for the acute and ambulatory care markets.

“I’m excited to join Spectrum at a time of strong momentum and opportunity,” Shook said. “With a differentiated portfolio and clear focus on infection prevention, we’re well-positioned to expand our market presence and deepen our impact across healthcare systems.”

Spectrum Vascular is a medical device company focused on vascular access and medication management. Innovation has been a core strategic pillar throughout Spectrum Vascular’s history and many of its products have been designed to deliver antimicrobial protection and thrombus reduction. Spectrum Vascular was formed through the acquisition of the vascular access businesses of Cook Medical and AngioDynamics.

SK Capital is a private investment firm with a disciplined focus on the specialty materials, ingredients, and life sciences sectors. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital’s portfolio of businesses generates revenues of approximately $12 billion annually, employs more than 25,000 people globally, and operates over 200 plants in 30-plus countries. SK Capital currently has approximately $9 billion in assets under management.

Event Capital Strategies is a medical technology-focused investment firm based in New York City, investing broadly across the healthcare sector with a particular focus on medication management, orthopedics, life sciences, diagnostics, and healthcare IT and services. ECS leverages experienced operating partners from healthcare and pharmaceutical companies, as well as medical doctors, to provide hands-on strategic and functional support to portfolio companies. The firm’s approach focuses on fundamental operational, managerial, and financial improvements that drive returns through execution and value creation.